The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented has been only approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of CKD associated with T2D in adults. For other approvals, follow your local regulations or health authorities legislation. The compound is not approved for non-diabetic CKD.
World Congress of Nephrology, 2022Industry Session Sponsored by Bayer February 24–27, 2022
Presentations of the Bayer Industry Symposium at WCN 2022
Thank you for your interest! See below to watch the session recording of the WCN’22 symposium video.
Finerenone
Saturday 26 February, 2022 | 09:30 - 10:30 CET | On Demand
Nonsteroidal MRAs: Expanding the evidence base in CKD and T2D and exploring new opportunities
The symposium offers a unique opportunity to gain insight into the cardiorenal benefits of finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, across the spectrum of CKD severity in patients with T2D.
Session type: Industry Sponsored Symposium Faculty: Juliana Chan, Meg Jardine, Christoph Wanner
View Video
More Information
For more information regarding Finerenone visit us by clicking the link below
At the moment of publication, the compound presented has been only approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of CKD associated with T2D in adults. For other approvals, follow your local regulations or health authorities legislation. The compound is not approved for non-diabetic CKD.
Date accessed: 25 February, 2022
MA-M_FIN-ALL-0704-1